专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20030068373A1 Immediate release tablet 有权
标题翻译：立即释放片剂
公开(公告)号：US20030068373A1
公开(公告)日：2003-04-10
申请号：US09966493
申请日：2001-09-28
发明人： Joseph Luber , Frank J. Bunick
IPC分类号： A61K009/20 , A61K009/22 , A61K009/36
CPC分类号： A61K9/2059 , A61K9/2013
摘要： An immediate release tablet is provided. The tablet comprises at least 60 weight % of an active ingredient and powdered wax having a melting point greater than about 90null C. The tablet may advantageously be produced by direct compression. Although the wax is hydrophobic, the tablet has excellent disintegration.
摘要翻译：提供立即释放的药片。片剂包含至少60重量％的活性成分和熔点大于约90℃的粉末蜡。片剂可有利地通过直接压片制备。尽管蜡是疏水性的，但片剂具有优异的崩解性。

72. 发明申请

US20030065308A1 Ambulatory medical apparatus with hand held communication device 审中-公开
公开(公告)号：US20030065308A1
公开(公告)日：2003-04-03
申请号：US09768196
申请日：2001-01-22
发明人： Ronald J. Lebel , Varaz Shahmirian , Daniel H. Villegas , David Y. Choy , Philip T. Weiss , Paul M. Meadows
IPC分类号： A61K009/22
CPC分类号： A61M5/172 , A61B5/0002 , A61B5/14532 , A61B5/6847 , A61B2560/0209 , A61M5/14244 , A61M5/14276 , A61M5/168 , A61M5/16831 , A61M2005/14208 , A61M2205/18 , A61M2205/3507 , A61M2205/3523 , A61M2205/50 , A61M2205/581 , A61M2205/582 , A61M2205/6018 , A61M2205/8206 , A61M2207/00 , A61N1/37211 , A61N1/37247 , A61N1/37252 , A61N1/37258 , A61N1/37264 , A61N1/3727 , A61N1/37276 , A61N1/375 , G06F3/0619 , G06F3/065 , G06F3/0673 , G06F8/60 , G06F8/65 , G06F19/3468 , G06Q50/22 , G16H40/40 , Y02D10/42 , Y10S128/13 , Y10S128/903 , Y10T29/49117 , Y10T29/49826
摘要： A communication device (CD) exchanges messages with an implantable infusion pump via telemetry such that commands are supplied thereto and operational information is obtained therefrom. The CD is controlled, at least in part, by a processor IC according to a software program operating therein and provides feedback to a user via a visual display, an audio alarm, and a vibrational alarm, and allows input from the user via a touch sensitive keypad. Certain input functions are restricted by password. The visual display includes an icon and fixed element display region and a bitmap display region. The fixed element display region includes time and date displays, battery and drug level displays that decrement, and a moving delivery state display. Various screens allow operational or log information to be displayed and/or user entry of commands. Program features when disabled are removed from a series of screen options that can be scrolled through.

73. 发明申请

US20030064088A1 Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues 有权
标题翻译：用于将治疗剂单向递送至组织的可植入和密封系统
公开(公告)号：US20030064088A1
公开(公告)日：2003-04-03
申请号：US10231767
申请日：2002-08-28
发明人： Ricardo Azevedo Pontes de Carvalho , Alan Linn Murphree , Edward E. Schmitt
IPC分类号： A61M036/14 , A61K051/00 , A61K048/00 , A61K038/27 , A61K039/395 , A61K009/22 , A61K031/56
CPC分类号： A61F2/02 , A61F9/0017 , A61F2210/0004 , A61F2250/0067 , A61F2250/0068 , A61K9/0051
摘要： A surgically implantable and sealable delivery device that upon contact of its contents via an interface window or port therein with an organ or tissue exposes a therapeutic agent to the organ or tissue surface, allowing a controlled, selective and unidirectional diffusion of the agent into the tissue or organ. The device protects adjacent organs or tissue structures from unnecessary high levels of the delivered agent. Novel methods to deliver chemotherapeutics or bioactive agents to mammalian organs or tissues through a surgically implanted device by the way of a selective and protected diffusion mechanism are disclosed as well as method to achieve the sealing properties of the device.
摘要翻译：手术可植入和可密封的递送装置，其内容物经由其中的界面窗口或口与其中的器官或组织接触将治疗剂暴露于器官或组织表面，允许药剂受控的，选择性的和单向的扩散到组织中或器官。该装置保护邻近的器官或组织结构免受不必要的高水平的递送的药剂。公开了通过选择性和保护的扩散机制通过手术植入的装置将化学治疗剂或生物活性剂递送到哺乳动物器官或组织的新方法以及实现装置密封性能的方法。

74. 发明申请

US20030055407A1 Microtubes for therapeutic delivery 有权
标题翻译：用于治疗性输送的微管
公开(公告)号：US20030055407A1
公开(公告)日：2003-03-20
申请号：US09954179
申请日：2001-09-18
发明人： Steven Walik
IPC分类号： A61K009/22
CPC分类号： A61L26/0061 , A61L26/0066 , A61L27/50 , A61L27/54 , A61L29/14 , A61L29/16 , A61L31/14 , A61L31/16 , A61L2300/622
摘要： A medical implant that delivers therapeutic via microtubes and a method of making the same is provided. In one embodiment a biologically implantable structure adapted to fit within the body of a patient is provided. This structure may have a plurality of individual microtubes in physical communication with its outer surface, the microtubes containing or carrying a therapeutic. In an alternative embodiment a method of manufacturing an implantable medical appliance is provided. This method includes placing a pliant stratum of microtubes onto a biologically implantable medical structure and then applying a therapeutic to the pliant stratum to cover or fill the microtubes.
摘要翻译：提供通过微管递送治疗剂的医疗植入物及其制备方法。在一个实施例中，提供了适于装配在患者体内的生物可植入结构。该结构可以具有与其外表面物理连通的多个单独的微管，所述微管包含或携带治疗剂。在替代实施例中，提供了一种制造可植入医疗器具的方法。该方法包括将柔性层的微管放置在生物可植入医疗结构上，然后将治疗剂施用于柔性层以覆盖或填充微管。

75. 发明申请

US20030055406A1 Ambulatory medical apparatus with hand held communication device 有权
标题翻译：手持通讯装置的动态医疗器械
公开(公告)号：US20030055406A1
公开(公告)日：2003-03-20
申请号：US09768198
申请日：2001-01-22
发明人： Ronald J. Lebel , Varaz Shahmirian , Daniel H. Villegas , David Y. Choy , Philip T. Weiss , Paul M. Meadows
IPC分类号： A61K009/22
CPC分类号： A61M5/172 , A61B5/0002 , A61B5/14532 , A61B5/6847 , A61B2560/0209 , A61M5/14244 , A61M5/14276 , A61M5/168 , A61M5/16831 , A61M2005/14208 , A61M2205/18 , A61M2205/3507 , A61M2205/3523 , A61M2205/50 , A61M2205/581 , A61M2205/582 , A61M2205/6018 , A61M2205/8206 , A61M2207/00 , A61N1/37211 , A61N1/37247 , A61N1/37252 , A61N1/37258 , A61N1/37264 , A61N1/3727 , A61N1/37276 , A61N1/375 , G06F3/0619 , G06F3/065 , G06F3/0673 , G06F8/60 , G06F8/65 , G06F19/00 , G06F19/3468 , G06Q50/22 , G16H40/40 , Y02D10/42 , Y10S128/13 , Y10S128/903 , Y10T29/49117 , Y10T29/49826
摘要： A communication device (CD) exchanges messages with an implantable infusion pump via telemetry such that commands are supplied thereto and operational information is obtained therefrom. The CD is controlled, at least in part, by a processor IC according to a software program operating therein and provides feedback to a user via a visual display, an audio alarm, and a vibrational alarm, and allows input from the user via a touch sensitive keypad. Certain input functions are restricted by password. The visual display includes an icon and fixed element display region and a bitmap display region. The fixed element display region includes time and date displays, battery and drug level displays that decrement, and a moving delivery state display. Various screens allow operational or log information to be displayed and/or user entry of commands. Program features when disabled are removed from a series of screen options that can be scrolled through.
摘要翻译：通信设备（CD）通过遥测与可植入输液泵交换消息，从而向其提供命令并获得操作信息。 CD至少部分地由处理器IC根据其中操作的软件程序进行控制，并通过视觉显示，音频报警和振动报警向用户提供反馈，并允许用户通过触摸进行输入敏感键盘。某些输入功能受密码限制。视觉显示器包括图标和固定元件显示区域和位图显示区域。固定元件显示区域包括时间和日期显示，递减的电池和药物水平显示以及移动的传送状态显示。各种屏幕允许显示操作或日志信息和/或用户输入命令。禁用时的程序功能从可以滚动的一系列屏幕选项中删除。

76. 发明申请

US20030050621A1 Safety limits for closed-loop infusion pump control 有权
公开(公告)号：US20030050621A1
公开(公告)日：2003-03-13
申请号：US10033530
申请日：2001-12-26
发明人： Ronald J. Lebel , Timothy Starkweather
IPC分类号： A61K009/22
CPC分类号： A61M5/1723 , A61M5/14276 , A61M5/172 , A61M2005/14208 , A61M2205/52 , A61M2207/00 , A61M2230/005 , A61M2230/201 , G06F19/00 , G06F19/3468 , Y10T29/49826
摘要： A system and process for providing safety limits on the delivery of an infusion formulation by an infusion pump system in response to a sensed biological state. The safety limits may comprise user-initiated event signals corresponding to events that may significantly affect the biological state. The safety limits may further comprise user-initiated event ranking signals for respective events which specify a degree, quantity, or measure for the respective event. The user-initiated event and event ranking signals may be communicated to a computing element associated with the infusion pump by an associated communication device having a user interface which comprises a plurality of user-selectable operators for entering information about the events and event rankings.

77. 发明申请

US20030039690A1 Controlled release arginine alpha ketoglutarate 失效
标题翻译：控制释放精氨酸α酮戊二酸
公开(公告)号：US20030039690A1
公开(公告)日：2003-02-27
申请号：US10226646
申请日：2002-08-23
发明人： Edward A. Byrd
IPC分类号： A61K031/198 , A61K009/22
CPC分类号： A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/5026 , A61K31/197 , A61K31/385 , A61K31/425 , A61K31/51 , A61K31/64 , A61K2300/00
摘要： An oral formulation of arginine null-ketoglutarate is disclosed which formulation is comprised of arginine null-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine null-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine null-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine null-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine null-ketoglutarate formulation.
摘要翻译：公开了精氨酸α-酮戊二酸的口服制剂，该制剂由精氨酸α-酮戊二酸和一种或多种赋形剂组成。在阅读本公开内容后，各种不同的控制释放制剂对于本领域技术人员是显而易见的。设计精氨酸α-酮戊二酸和赋形剂材料，以获得所需的结果，例如，减轻患有谷氨酸脱氢酶缺乏症的患者所遭受的症状或增加脯氨酰羟化酶和赖氨酰羟化酶活性或阻止动脉粥样硬化，白内障形成，视网膜病变和衰老的蛋白质糖化特征。期望的结果是通过增加在患者体内持续维持治疗水平的α-酮戊二酸的治疗水平而获得的。治疗水平以及必须保持该水平的时间段可以在患者基于诸如患者的状况和患者对精氨酸α-酮戊二酸的反应性的一系列因素之间变化。然而，该时间段将大于用常规快速释放精氨酸α-酮戊二酸酯制剂获得的时间。

78. 发明申请

US20030035834A1 Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release 审中-公开
标题翻译：持续释放的维拉帕米药物组合物不含食物作用，并且是减轻药物释放中食物作用的方法
公开(公告)号：US20030035834A1
公开(公告)日：2003-02-20
申请号：US09583228
申请日：2000-05-26
发明人： Pawan Seth
IPC分类号： A61K009/22 , A61K009/14
CPC分类号： A61K9/2846 , A61K9/2813 , A61K9/2886
摘要： The invention provides a sustained release composition free of food effect comprising: (a) a core comprising verapamil; and (b) a functional coating comprising, based on the weight of the coating, from 30 to 80% of a gastroresistant polymer and from 10 to 40% of a hydrophilic silicon dioxide. The invention also provides a method for alleviating food effect in a verapamil pharmaceutical composition.
摘要翻译：本发明提供一种不含食物效应的缓释组合物，其包含：（a）包含维拉帕米的核心; 和（b）功能性涂层，其包含基于涂层重量的30至80％的耐胃聚合物和10至40％的亲水性二氧化硅。本发明还提供了一种减轻维拉帕米药物组合物中食物作用的方法。

79. 发明申请

US20020197315A1 Controlled release composite 有权
标题翻译：控释复合材料
公开(公告)号：US20020197315A1
公开(公告)日：2002-12-26
申请号：US09999253
申请日：2001-11-01
申请人： Wright Medical Technology, Inc. a Delaware Corporation
发明人： Warren Oliver Haggard , Michael Earl Kaufman , Jack Eldon Parr , Linda Morris
IPC分类号： A61K038/14 , A61K038/13 , A61K009/22 , A61K031/525
CPC分类号： A61K9/167 , A61K9/1611 , A61K9/501
摘要： A composite is disclosed having a controlled rate of dissolution. The composite includes (a) a first region that includes a first composition that includes calcium sulfate, the first region exhibiting a first rate of dissolution; and (b) a second region that includes a second composition that includes calcium sulfate, the second region exhibiting a second rate of dissolution, the first rate of dissolution being different from the second rate of dissolution
摘要翻译：公开了具有受控的溶解速率的复合材料。所述复合物包括（a）第一区域，其包括第一组合物，所述第一组合物包括硫酸钙，所述第一区域呈现出第一溶解速率; 和（b）第二区域，其包括包含硫酸钙的第二组合物，所述第二区域呈现第二溶解速率，所述第一溶解速率与所述第二溶解速率不同

80. 发明申请

US20020182252A1 PH-DEPENDENT SUSTAINED RELEASE, DRUG-DELIVERY COMPOSITION 失效
标题翻译： PH依赖性持续发布，药物输送组合物
公开(公告)号：US20020182252A1
公开(公告)日：2002-12-05
申请号：US09814084
申请日：2001-03-21
申请人： ISP INVESTMENTS INC.
发明人： Antonio Moroni , William Drefko
IPC分类号： A61K031/522 , A61K009/22 , A61K031/275 , A61K009/14
CPC分类号： A61K9/205
摘要： A pH-dependent sustained release, drug delivery composition capable of being formed into tablets or pellets, wherein the release is controlled by a diffusion barrier formed by the interaction of a pH-dependent gelling material and a pH-independent non-gelling material, comprising a polymer matrix comprising, by weight, (a) 10 to 50% sodium alginate, (b) 2 to 15% propylene glycol alginate and (c) 40 to 80% of a pharmaceutical medicament.
摘要翻译： pH依赖性缓释药物递送组合物，其能够形成片剂或丸粒，其中释放由通过pH依赖性凝胶材料和pH非依赖性胶凝材料的相互作用形成的扩散屏障控制，包括包含（a）10-50％藻酸钠，（b）2-15％丙二醇藻酸盐和（c）40-80％药物的聚合物基质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式